Latest Breaking News On - Precision timed release - Page 1 : comparemela.com

FDA Clears Cingulate to File for Marketing Approval of

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application Advancing Discussions with Commercialization Partners.

United statesKansas cityShanej schafferMatt krepsThomas daltonAnn childressDarrow associatesExchange commissionPsych congress first annual posterDrug administrationAmerican professional societyBehavior medicine incSecurities exchangePsych congressPlatform technologyCingulate inc

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD

Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application CTx-1301 Could Benefit >60% of ADHD Patients Currently .

United statesKansas cityShanej schafferMatt krepsThomas daltonAnn childressDrug administrationBehavior medicine incPlatform technologySecurities exchangeDarrow associatesPsych congress first annual posterExchange commissionPsych congressCingulate incAmerican professional society

FDA New Drug Application In The Works For This Innovator In ADHD Drug Delivery

FDA New Drug Application In The Works For This Innovator In ADHD Drug Delivery
biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.

Peterj werthShane schafferBoard memberPrecision timed release

Peter J Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board

KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and

United statesKansas cityThomas daltonShanej schafferPeterj werthMatt krepsBenzinga youtubeSecurities exchangeExchange commissionChemwerth incCingulate incDarrow associatesPrecision timed releaseCingulate chairmanBenzinga all accessFriday may

Peter J Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J Schaffer on Benzinga All Live Access

KANSAS CITY, Kan., April 30, 2024 Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a.

Kansas cityUnited statesThomas daltonBenzinga youtubeShanej schafferMatt krepsPeterj werthExchange commissionSecurities exchangeChemwerth incDarrow associatesGlobenewswire incCingulate incPrecision timed releaseBenzinga all accessWerth inc